A field that stops publishing may be a field where negative results went unpublished
More frequent monitoring may be needed if symptoms or TSH changes emerge during weight loss
Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G et al
FOXO4-DRI theoretically has higher selectivity by targeting the FOXO4-p53 interaction that is specifically elevated in senescent cells
In the SURMOUNT-5 head-to-head trial, adults on Tirzepatide lost more weight than adults on semaglutide over 72 weeks about 20% versus 14% of body weight plus bigger reductions in waist size
Administered as a once-weekly injection, Tirzepatide helps slow digestion, decrease cravings, and support more sustainable weight loss